Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 979 CHF -0.2%
Market Cap: 4.4B CHF
Have any thoughts about
Siegfried Holding AG?
Write Note

Siegfried Holding AG
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Siegfried Holding AG
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Current Portion of Long-Term Debt
CHf146k
CAGR 3-Years
-90%
CAGR 5-Years
-69%
CAGR 10-Years
-42%
Lonza Group AG
SIX:LONN
Current Portion of Long-Term Debt
CHf191m
CAGR 3-Years
-39%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Tecan Group AG
SIX:TECN
Current Portion of Long-Term Debt
CHf11.5m
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Current Portion of Long-Term Debt
€46.9m
CAGR 3-Years
57%
CAGR 5-Years
49%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Current Portion of Long-Term Debt
CHf870k
CAGR 3-Years
-9%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Market Cap
4.2B CHF
Industry
Life Sciences Tools & Services

Nestled in the picturesque landscapes of Zofingen, Switzerland, Siegfried Holding AG operates as a key player in the global pharmaceutical supply chain, crafting a narrative of innovation and precision. With roots tracing back to 1873, this stalwart company has evolved over the decades, now standing as a leading supplier of active pharmaceutical ingredients (APIs) and finished dosage forms to the pharmaceutical industry. Siegfried's operations are defined by a seamless integration of chemistry and technology, embodying Swiss precision in every facet of its production process. The company's trajectory is marked by strategic expansions and acquisitions, allowing it to amass a presence in both Europe and North America, crafting a network that ensures its reliability and reach. At the heart of Siegfried's success lies its business model, a symbiotic partnership with pharmaceutical companies that rely on its vast expertise to bring their products to market. Siegfried essentially straddles both ends of the pharmaceutical value chain, deriving revenue by providing essential APIs as well as a robust offering of finished drugs. The company excels in tailor-made solutions, offering complex manufacturing processes that meet stringent regulatory demands. This dual capability not only diversifies its revenue streams but also buffers it against the volatile dynamics of the pharmaceutical industry. With a focus on quality and customer-centric innovation, Siegfried continues to carve a niche as a trusted collaborator, underpinning the development of health solutions worldwide.

SFZN Intrinsic Value
1 168.32 CHF
Undervaluation 16%
Intrinsic Value
Price

See Also

Back to Top